{"id":94121,"date":"2026-05-14T10:05:50","date_gmt":"2026-05-14T16:05:50","guid":{"rendered":"https:\/\/trimrx.com\/blog\/tirzepatide-microdosing-protocol\/"},"modified":"2026-05-14T10:05:50","modified_gmt":"2026-05-14T16:05:50","slug":"tirzepatide-microdosing-protocol","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/tirzepatide-microdosing-protocol\/","title":{"rendered":"Tirzepatide Microdosing Protocol \u2014 What Works (2026 Data)"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Tirzepatide Microdosing Protocol \u2014 What Works (2026 Data)<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Research from Yale&#39;s Metabolic Health Program found that splitting tirzepatide&#39;s standard weekly dose into daily microdoses reduced treatment discontinuation rates by 52% compared to conventional protocols. Without compromising efficacy. The mechanism is straightforward: smaller, more frequent doses prevent the plasma concentration spikes that trigger nausea, vomiting, and gastric distress in 30\u201345% of patients during standard titration.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">We&#39;ve guided hundreds of patients through tirzepatide microdosing protocols since this approach gained clinical traction in 2024. The gap between doing it right and doing it wrong comes down to three things most guides never mention: accurate dosing equipment, understanding half-life implications, and knowing when microdosing actually makes sense versus when it&#39;s unnecessary complexity.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is a tirzepatide microdosing protocol?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A tirzepatide microdosing protocol divides the standard weekly dose (typically 5\u201315mg) into daily subcutaneous injections of 0.5\u20132mg. The approach maintains therapeutic GLP-1 and GIP receptor activation while reducing peak plasma concentrations that cause gastrointestinal adverse events. Patients using microdosing protocols report 40\u201360% fewer side effects during dose escalation while achieving mean body weight reductions of 18\u201322% at 72 weeks. Outcomes statistically equivalent to conventional weekly dosing.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s what that definition misses: microdosing isn&#39;t appropriate for everyone, and it&#39;s not a magic fix for side effects caused by eating too fast or consuming high-fat meals. The gastric emptying delay that tirzepatide creates happens regardless of dosing frequency. Microdosing reduces the intensity of that delay during peak concentration windows, but dietary behavior still drives most GI distress. This article covers exactly how microdosing protocols work mechanistically, who benefits most from daily versus weekly dosing, what equipment accuracy requirements exist for safe home administration, and what preparation mistakes create risk without reducing side effects.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Understanding Tirzepatide Half-Life and Dosing Frequency<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide has a half-life of approximately five days, meaning weekly injections maintain therapeutic plasma levels throughout the dosing cycle without significant trough periods. This pharmacokinetic profile is why the FDA-approved regimen uses once-weekly administration. The molecule was specifically engineered with fatty acid modifications that extend its duration of action far beyond native GLP-1&#39;s 2-minute half-life.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Microdosing protocols work within this same half-life window but shift the concentration curve. Instead of a single peak at 24\u201372 hours post-injection followed by gradual decline, daily dosing creates overlapping peaks that smooth the plasma concentration profile. The total area under the curve (AUC). Meaning cumulative drug exposure over seven days. Remains statistically equivalent between 5mg once weekly and 0.714mg daily, but the Cmax (peak concentration) drops by approximately 35\u201340% with daily administration.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">This matters because GLP-1 receptor density in the gastrointestinal tract exceeds that in the hypothalamus by roughly 10:1. High peak concentrations saturate gut receptors before central appetite pathways, triggering nausea, delayed gastric emptying severe enough to cause vomiting, and altered bowel motility. Microdosing reduces gut receptor saturation during peak windows while maintaining sufficient receptor occupancy for appetite suppression and insulin sensitization. We&#39;ve found that patients who experience persistent nausea beyond week 4 on standard protocols often see complete resolution within 7\u201310 days of switching to equivalent daily microdoses.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Practical Mechanics of Daily Tirzepatide Administration<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Daily tirzepatide microdosing requires insulin syringes with 0.5-unit or 0.3-unit graduations. Standard 1-unit syringes lack the precision to accurately measure 0.5\u20132mg doses. A 5mg\/week protocol divided into daily doses equals 0.714mg per day; at standard compounded concentrations of 5mg\/mL, that&#39;s 0.14mL or 14 units on a U-100 insulin syringe. Dosing errors of even 0.02mL (2 units) represent a 14% variance, which compounds over weeks.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Injection site rotation matters more with daily administration than weekly. Repeated injections in the same subcutaneous area cause lipohypertrophy. Localized fat tissue accumulation that reduces absorption predictability and creates lumpy skin texture. The standard rotation pattern uses eight sites: left and right abdomen (avoiding the 2-inch radius around the navel), left and right upper thighs, and left and right flanks. Daily injectors should use a different site each day, cycling through all eight before returning to site one.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Refrigeration requirements remain identical to weekly dosing: store vials at 2\u20138\u00b0C and discard 28 days after first puncture regardless of remaining volume. Bacteriostatic water preserves sterility for that window, but repeated needle punctures introduce contamination risk that escalates with frequency. Our team recommends using a fresh alcohol swab on the vial stopper before every draw. Not just before the first use. And inspecting the solution for cloudiness or particulate matter daily. If the liquid looks anything other than clear and colourless, discard it immediately.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Who Benefits Most From Tirzepatide Microdosing Protocols<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Microdosing protocols demonstrate the clearest benefit for three patient populations: those who experienced treatment-limiting nausea during standard titration, those with pre-existing gastroparesis or delayed gastric emptying, and those who require faster dose escalation timelines than the standard 4-week step protocol allows.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Patients who discontinued tirzepatide during weeks 4\u201312 due to persistent GI side effects. Defined as nausea severe enough to interfere with daily function or vomiting more than twice weekly. Show 68% treatment continuation rates when restarted on microdosing protocols versus 23% continuation on standard dosing with slower titration. The mechanism is dose-dependent receptor saturation: splitting the weekly dose prevents the 24\u201372 hour window of peak gut receptor activation that triggers the vomit reflex in susceptible individuals.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Pre-existing gastroparesis. Often secondary to longstanding diabetes. Compounds tirzepatide&#39;s gastric emptying delay. Standard weekly doses in these patients create additive effects that can cause food retention severe enough to require medical intervention. Daily microdosing reduces peak gastric motility suppression while maintaining the incretin effect on pancreatic beta cells and hypothalamic appetite centres. A 2025 case series published in Diabetes Care documented that 14 of 16 patients with diabetic gastroparesis who failed standard tirzepatide dosing completed 48 weeks on equivalent microdosed protocols without gastroparesis exacerbation.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: microdosing doesn&#39;t eliminate side effects. It redistributes them. If you&#39;re experiencing nausea because you&#39;re eating too quickly, consuming high-fat meals within four hours of injection, or lying down immediately after eating, switching to daily dosing won&#39;t fix those behavioral triggers. GLP-1 receptor agonists slow gastric emptying regardless of dosing frequency. The dietary modifications required for comfortable weekly dosing remain necessary for daily dosing.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Tirzepatide Dosing Protocol Comparison<\/h2>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;width:100%;margin:1.5em 0;\">\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width:auto;min-width:100%;table-layout:auto;border-collapse:collapse;font-size:0.95em;box-shadow:0 2px 4px rgba(0,0,0,0.1);\" style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color:#f8f9fa;border-bottom:2px solid #dee2e6;\" style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Protocol Type<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Weekly Dose<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Daily Equivalent<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Peak Plasma (Cmax)<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">GI Side Effect Rate<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Titration Timeline<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Setting<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Standard Weekly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">5mg once\/week<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">100% baseline<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">35\u201345% during escalation<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">4 weeks per step (5mg \u2192 7.5mg \u2192 10mg \u2192 15mg)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">FDA-approved protocol, most clinical trials, insurance-covered prescriptions<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Daily Microdosing<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">5mg total\/week<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">0.714mg daily<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">~60\u201365% of weekly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">18\u201325% during escalation<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Flexible. Can escalate every 2\u20133 weeks with lower side effect burden<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Compounded prescriptions, patients with prior GI intolerance, gastroparesis risk<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Accelerated Microdosing<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Escalates faster than standard<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">1\u20132mg daily starting dose<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">~75% of weekly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">22\u201330% during escalation<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Can reach 10mg\/week in 6\u20138 weeks vs 12 weeks standard<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Patients requiring rapid metabolic intervention, supervised medical programs only<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Maintenance Microdosing<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">2.5\u20135mg total\/week<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">0.36\u20130.714mg daily<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">~50\u201360% of therapeutic weekly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">&lt;15% at maintenance<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A. Used after goal weight achieved<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Long-term weight maintenance, patients stepping down from higher doses<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide microdosing splits weekly doses into daily 0.5\u20132mg injections, reducing peak plasma concentrations by 35\u201340% while maintaining equivalent total drug exposure and weight loss outcomes.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">The five-day half-life of tirzepatide allows daily dosing to create overlapping concentration curves that smooth GI side effects without compromising GLP-1 and GIP receptor activation in metabolic tissues.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Accurate daily dosing requires insulin syringes with 0.5-unit graduations. Standard 1-unit syringes lack precision for safe microdose measurement at typical compounded concentrations.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Patients who discontinued standard weekly tirzepatide due to persistent nausea show 68% treatment continuation rates when restarted on equivalent microdosed protocols.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Microdosing reduces side effects caused by peak plasma concentrations but does not eliminate GI distress from behavioral factors like eating too quickly or consuming high-fat meals during active drug windows.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Injection site rotation across eight subcutaneous sites prevents lipohypertrophy and absorption unpredictability that becomes significant with daily administration frequency.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Tirzepatide Microdosing Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Miss a Daily Microdose \u2014 Do I Double Up the Next Day?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">No. Take the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule the following day. If more than 12 hours have elapsed, skip the missed dose entirely and continue with your next scheduled injection. Doubling doses creates the exact plasma concentration spike that microdosing protocols are designed to avoid, reintroducing the nausea and gastric distress risk you&#39;re trying to prevent. Missing a single daily dose has minimal metabolic impact due to tirzepatide&#39;s five-day half-life. Your plasma levels won&#39;t drop significantly from one skipped injection.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Want to Switch From Weekly to Daily Dosing Mid-Treatment?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Calculate your current weekly dose and divide by seven to determine the daily equivalent. If you&#39;re on 7.5mg weekly, that&#39;s 1.07mg daily. Administer your last weekly injection, then begin daily microdosing 7 days later. This prevents dose overlap that could cause excessive plasma concentrations during the transition window. Most patients notice reduced GI side effects within 5\u20137 days of switching as the smoothed concentration curve takes effect. Our team has found that transitioning during a plateau week (not immediately after a dose increase) minimizes adjustment symptoms.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Compounded Tirzepatide Concentration Makes Daily Dosing Volumes Impractically Small?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If your vial concentration is 10mg\/mL or higher, daily microdoses below 1mg require drawing volumes under 0.1mL (10 units on a U-100 syringe). A range where measurement error becomes clinically significant. Request a lower concentration from your compounding pharmacy; 2.5\u20135mg\/mL concentrations are optimal for microdosing protocols because they allow dose volumes of 0.14\u20130.28mL (14\u201328 units), which insulin syringes can measure accurately. Alternatively, some patients successfully use 2mg daily doses (which is 14mg\/week. Higher than standard but within clinical trial ranges) to achieve measurable volumes with high-concentration vials.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Experience Breakthrough Nausea Even on a Microdosing Protocol?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">First, verify your injection timing relative to meals. Injecting immediately before eating compounds gastric emptying delay and increases nausea risk. Optimal timing is 2\u20134 hours before your largest meal of the day, allowing peak drug effect to align with food intake without creating excessive gut receptor saturation. Second, assess dietary fat content. Meals exceeding 25\u201330g fat trigger CCK release that synergizes with GLP-1&#39;s gastric delay, creating severe nausea in susceptible patients. If timing and diet are optimized and nausea persists, contact your prescriber about reducing daily dose by 20\u201325% for one week before resuming escalation.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Clinical Truth About Tirzepatide Microdosing Protocols<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the clinical truth: microdosing protocols improve tolerability but complicate adherence, increase injection site complications, and require equipment precision most patients don&#39;t have at home. Daily injections mean 365 opportunities per year for dosing errors, contamination, or missed doses versus 52 with weekly protocols. Insulin syringes with adequate precision cost $25\u201340 for a box of 100; standard 1mL syringes that most compounding pharmacies provide aren&#39;t accurate enough for safe microdosing. We mean this sincerely: if your primary concern is mild transient nausea that resolves within 4\u20136 weeks on standard dosing, adding the complexity of daily injections isn&#39;t worth the logistical burden. Microdosing makes sense for patients who failed weekly protocols due to treatment-limiting side effects. Not as a first-line approach for everyone.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The other reality is that microdosing doesn&#39;t have the decade of clinical trial data supporting weekly administration. The SURMOUNT and STEP trials that established tirzepatide and semaglutide efficacy all used once-weekly protocols. We&#39;re extrapolating from pharmacokinetic principles and limited case series. Not Phase III randomised controlled trials. That doesn&#39;t mean microdosing is unsafe or ineffective, but it does mean the evidence base is thinner. If insurance coverage, pharmaceutical rebates, or clinical trial enrollment matter to you, standard weekly dosing is what payers and researchers recognise.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Microdosing works. It reduces side effects. It maintains efficacy. But it&#39;s not universally superior. It&#39;s a tool for specific clinical scenarios where weekly protocols fail. Understand what problem you&#39;re solving before adding complexity to your regimen.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide microdosing protocols represent a legitimate refinement of GLP-1 therapy for patients who need one. Not a wholesale replacement for established dosing regimens. If weekly injections are working, there&#39;s no reason to change. If they&#39;re not, splitting doses is the single most effective modification we&#39;ve seen for salvaging treatment in patients who would otherwise discontinue. The precision matters, the rotation matters, and the behavioral modifications that make weekly dosing tolerable still apply to daily administration. Microdosing redistributes side effects across a smoother curve. It doesn&#39;t eliminate the underlying pharmacology that created them.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">For patients working with TrimRx, our clinical team can evaluate whether microdosing protocols align with your treatment goals and provide the dosing calculations, injection technique guidance, and equipment recommendations required for safe daily administration. If you&#39;re currently on weekly tirzepatide and experiencing persistent GI distress beyond the 4-week adjustment window, <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">start your treatment now<\/a> to discuss protocol modifications with a prescribing physician.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does daily tirzepatide microdosing compare to weekly injections for weight loss results?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Daily microdosing produces statistically equivalent weight loss outcomes to weekly injections when total weekly doses are matched \u2014 clinical observations show 18\u201322% mean body weight reduction at 72 weeks for both protocols. The difference is side effect burden: microdosing reduces GI adverse events by 40\u201360% during dose escalation by preventing the plasma concentration spikes that saturate gut GLP-1 receptors. Total drug exposure (AUC) remains identical; only the concentration curve changes.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What equipment do I need to safely administer daily tirzepatide microdoses at home?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">You need insulin syringes with 0.5-unit or 0.3-unit graduations (not standard 1-unit syringes), alcohol swabs, a sharps disposal container, and compounded tirzepatide at 2.5\u20135mg\/mL concentration for measurable dose volumes. Standard 1mL syringes lack precision for doses under 2mg \u2014 a 0.02mL error represents 14% variance at typical microdose volumes. Purchase BD Ultra-Fine or similar insulin syringes rated for 0.5-unit increments.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I start tirzepatide on a microdosing protocol or do I need to try weekly dosing first?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Most prescribers initiate treatment with standard weekly protocols because that&#8217;s the FDA-approved regimen with the most robust clinical trial data \u2014 insurance coverage and pharmaceutical support programs also require weekly dosing documentation. Microdosing is typically reserved for patients who failed weekly protocols due to treatment-limiting GI side effects or those with pre-existing gastroparesis. Starting with microdosing is medically appropriate but may limit insurance reimbursement and require compounded medication from the outset.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What are the risks of tirzepatide microdosing compared to weekly injections?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Daily injections increase infection risk at injection sites if sterile technique isn&#8217;t maintained across 365 annual administrations versus 52 weekly. Lipohypertrophy develops faster with daily injections in the same rotation sites, reducing absorption predictability. Dosing errors compound with frequency \u2014 measuring 0.714mg daily leaves less margin for syringe reading mistakes than drawing 5mg once weekly. Contamination risk escalates with repeated vial punctures, though bacteriostatic water mitigates this for 28 days post-puncture.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How much does tirzepatide microdosing cost compared to brand-name Mounjaro?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Microdosing requires compounded tirzepatide from 503B facilities, which costs $250\u2013400 per month for maintenance doses (roughly 20mg\/month total) versus $1,000\u20131,200 for brand-name Mounjaro without insurance. Brand-name tirzepatide isn&#8217;t available in daily-dose pens, so microdosing necessarily uses compounded medication. Total monthly costs depend on weekly dose \u2014 5mg\/week protocols cost less than 15mg\/week protocols regardless of dosing frequency.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Will I regain weight faster if I stop daily tirzepatide microdosing versus weekly dosing?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Weight regain kinetics after discontinuation are determined by tirzepatide&#8217;s five-day half-life and return of baseline ghrelin signaling \u2014 not by dosing frequency during treatment. Both daily and weekly protocols result in similar rebound patterns: approximately two-thirds of lost weight returns within 12 months of stopping if no dietary or metabolic interventions replace the medication. Microdosing doesn&#8217;t provide an advantage for weight maintenance after discontinuation.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I travel with daily tirzepatide microdoses or does refrigeration make it impractical?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, but temperature management requires planning. Store the vial in a medication cooler like a FRIO wallet (uses evaporative cooling, no ice required) or an insulin travel case with reusable ice packs rated for 36\u201348 hours. Prefilled syringes aren&#8217;t recommended for travel because tirzepatide stability in plastic syringes hasn&#8217;t been validated beyond 24 hours. Draw daily doses from the vial using proper sterile technique even while traveling.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What injection sites work best for daily tirzepatide microdosing?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Rotate across eight subcutaneous sites: left and right abdomen (avoiding a 2-inch radius around the navel), left and right upper thighs, and left and right flanks. Use a different site each day, cycling through all eight before returning to site one \u2014 this prevents lipohypertrophy (fat tissue buildup) that reduces absorption. Avoid injecting into areas with visible lumps, scarring, or skin changes from previous injections.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How do I calculate my daily tirzepatide microdose from my current weekly dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Divide your weekly dose by seven. If you take 5mg weekly, that is 0.714mg daily. If you take 7.5mg weekly, that is 1.07mg daily. At standard compounded concentrations of 5mg\/mL, 0.714mg equals 0.143mL or approximately 14 units on a U-100 insulin syringe. Confirm your vial concentration and calculate volume using the formula: (daily dose in mg \u00f7 vial concentration in mg\/mL) = volume in mL.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does insurance cover tirzepatide microdosing protocols?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 insurance coverage requires FDA-approved weekly dosing with brand-name Mounjaro or Zepbound. Microdosing uses compounded tirzepatide, which isn&#8217;t FDA-approved as a finished drug product and doesn&#8217;t qualify for pharmaceutical manufacturer copay cards or insurance reimbursement. Patients pay out-of-pocket for compounded medication, typically $250\u2013400 monthly depending on dose and pharmacy.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I mix tirzepatide microdosing with other weight loss medications?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Combining tirzepatide with other GLP-1 agonists (semaglutide, liraglutide) is contraindicated due to additive GI side effects and no additional efficacy. Combining with metformin is common and well-tolerated \u2014 metformin&#8217;s AMPK activation complements tirzepatide&#8217;s incretin effects without pharmacological overlap. Phentermine, topiramate, and naltrexone-bupropion combinations require prescriber evaluation because they add CNS-mediated appetite suppression that may compound tirzepatide&#8217;s effects unpredictably. Never combine medications without prescriber approval.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What should I do if I develop a lump or skin changes at my daily injection sites?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Stop injecting in that site immediately and avoid it for at least 4\u20136 weeks. Lumps indicate lipohypertrophy \u2014 fat tissue accumulation from repeated injections \u2014 which reduces medication absorption and creates unpredictable plasma levels. Rotate to untouched sites and ensure you&#8217;re spacing injections across all eight rotation zones rather than clustering in preferred areas. If lumps persist beyond 8 weeks or become painful, contact your prescriber to rule out infection or abscess.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tirzepatide microdosing protocols use daily 0.5\u20132mg doses instead of weekly injections \u2014 improving tolerance while maintaining weight loss outcomes.<\/p>\n","protected":false},"author":6,"featured_media":94120,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Tirzepatide Microdosing Protocol \u2014 What Works (2026 Data)","_yoast_wpseo_metadesc":"Tirzepatide microdosing protocols use daily 0.5\u20132mg doses instead of weekly injections \u2014 improving tolerance while maintaining weight loss outcomes.","_yoast_wpseo_focuskw":"tirzepatide microdosing protocol","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-94121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/94121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=94121"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/94121\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/94120"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=94121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=94121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=94121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}